TBPH

Theravance Biopharma Inc

Price:

8.27

USD

Volume:

172,583.00

Cayman Islands | Pharmaceuticals

The Probability of Bankruptcy of Theravance Biopharma Inc (TBPH) is **27.04%** . This number represents the probability that
TBPH will face financial distress in the next 24 months given its current fundamentals and
market conditions.

Multiple factors are taken into account when calculating TBPH's probability of bankruptcy : Altman Z-score, Beneish M-score, financial position, macro environments, academic research about distress risk and more.

ESG ratings are directly linked to the cost of capital and TBPH's ability to raise funding, both of which can significantly affect the probability of Theravance Biopharma Inc going bankrupt.

ESG Score | 52.12 |

Environment Score | 60.05 |

Social Score | 20.69 |

Governance Score | 75.62 |

Returns | |

Historical Returns (5 day) | 1.73% |

Historical Returns (MTD) | -0.12% |

Historical Returns (YTD) | -26.69% |

Historical Returns (13 week) | -2.83% |

Historical Returns (26 week) | -6.36% |

Historical Returns (52 week) | -7.00% |

Efficiency | |

Asset Turnover | 0.16 |

Receiveable Turnover | 4.12 |

Gross Margin | 100.00% |

Operating Margin | -110.16% |

Pretax Margin | -106.77% |

Net Margin | -115.94% |

Return on Asset (ROA) | -11.96 |

Return on Equity (ROE) | -21.32 |

Return on Investments (ROI) | -19.39 |

Price Metrics | |

Market Cap (M) | 404.57 |

Enterprise Value (M) | |

52 Week High | 11.71 |

52 Week Low | 7.44 |

Beta | 0.72 |

Average Volume (10 day) | 0.19 |

Average Volume (3 month) | 0.37 |

Price / Earnings (P/E) | |

Price / Sales (P/S) | 6.50 |

Earnings | |

EPS | -0.92 |

Revenue CAGR (5 year) | -1.01% |

Risk | |

Current Ratio | 5.20 |

Quick Ratio | 4.81 |